Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.95 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.95 |
| ▸ | ATM | Q13315 | 1/20 | 0.95 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.59 |
| ▸ | SLC9A1 | P19634 | 6/20 | 0.54 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | THPO | P40225 | 1/20 | 0.54 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.54 |
| ▸ | KCNMA1 | Q12791 | 3/20 | 0.48 |
| ▸ | MGAM | O43451 | 2/20 | 0.47 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | SI | P14410 | 2/20 | 0.47 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL28811644 | 1.00 | POLB (0.95) | POLBMAPK1ATMDGAT1SLC9A1 | |
| Water SCHEMBL12099335 | 1.00 | POLB (0.95) | POLBMAPK1ATMDGAT1SLC9A1 | |
| Water SCHEMBL29396172 | 1.00 | POLB (0.95) | POLBMAPK1ATMDGAT1SLC9A1 | |
| Water SCHEMBL1915155 | 1.00 | POLB (0.95) | POLBMAPK1ATMDGAT1SLC9A1 | |
| Water SCHEMBL5523 | 1.00 | POLB (0.95) | POLBMAPK1ATMDGAT1SLC9A1 | |
| Hydrochloric Acid SCHEMBL17967108 | 0.98 | POLB (0.91) | POLBMAPK1ATMDGAT1SLC9A1 | |
| Water SCHEMBL27491397 | 0.98 | POLB (0.91) | POLBMAPK1ATMDGAT1SLC9A1 | |
| Water SCHEMBL16962408 | 0.98 | POLB (0.91) | POLBMAPK1ATMDGAT1SLC9A1 | |
| Ammonia Solution, Strong SCHEMBL16319213 | 0.98 | POLB (0.91) | POLBMAPK1ATMDGAT1SLC9A1 | |
| SCHEMBL3672275 | 0.98 | POLB (1.00) | POLBMAPK1ATMDGAT1SLC9A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3481814-B1 | TETRAHYDRONAPHTHYRIDINEPENTANAMIDE INTEGRIN ANTAGONISTS | UNIV ROCKEFELLER (US) | 2022-04-27 | — | — | EP | disclosed |
| US-11192889-B2 | Tetrahydronaphthyridinepentanamide integrin antagonists | THE ROCKEFELLER UNIVERSITY (US) | 2021-12-07 | — | — | US | disclosed |
| US-20200181138-A1 | TETRAHYDRONAPHTHYRIDINEPENTANAMIDE INTEGRIN ANTAGONISTS | THE ROCKEFELLER UNIVERSITY (US) | 2020-06-11 | — | — | US | disclosed |
| EP-3481814-A1 | TETRAHYDRONAPHTHYRIDINEPENTANAMIDE INTEGRIN ANTAGONISTS | The Rockefeller University (US) | 2019-05-15 | — | — | EP | disclosed |
| CN-109476632-A | Tetrahydronaphthyridderivates pentanamide integrin antagonists | 洛克菲勒大学 | 2019-03-15 | — | — | CN | disclosed |
| WO-2018009501-A1 | TETRAHYDRONAPHTHYRIDINEPENTANAMIDE INTEGRIN ANTAGONISTS | THE ROCKEFELLER UNIVERSITY (US) | 2018-01-11 | — | — | WO | disclosed |
| EP-1730152-B1 | TETRAHYDROQUINOLINE DERIVATIVES AND A PROCESS FOR PREPARING THE SAME | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-8158640-B2 | Tetrahydroquinoline derivatives and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-04-17 | — | — | US | disclosed |
| EP-1979331-B1 | TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-8076364-B2 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-12-13 | — | — | US | disclosed |
| WO-2007088996-A1 | TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
| US-20070082896-A1 | Tetrahydroquinoline derivatives and a process for preparing the same | TANABE SEIYAKU CO., LTD. | 2007-04-12 | — | — | US | disclosed |
| CN-1938314-A | Tetrahydroquinoline derivatives and process for producing the same | TANABE SEIYAKU CO (JP) | 2007-03-28 | — | — | CN | disclosed |
| EP-1730152-A2 | TETRAHYDROQUINOLINE DERIVATIVES AND A PROCESS FOR PREPARING THE SAME | TANABE SEIYAKU CO., LTD. (JP) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005095409-A2 | TETRAHYDROQUINOLINE DERIVATIVES AND A PROCESS FOR PREPARING THE SAME | TANABE SEIYAKU CO., LTD. (JP) | 2005-10-13 | — | — | WO | disclosed |
| EP-1578735-A1 | CYCLOPENTYL GLUTARAMIDES AND THEIR USE AS NEUTRAL ENDOPEPTIDASE INHIBITORS | Pfizer Limited (GB) | 2005-09-28 | — | — | EP | disclosed |
| US-20040138274-A1 | Cardiovascular disorders; hypotensive agents; endopeptidase inhibitor; sexual disorders | DACK KEVIN NEIL (GB) | 2004-07-15 | — | — | US | disclosed |
| WO-2004056787-A1 | CYCLOPENTYL GLUTARAMIDES AND THEIR USE AS NEUTRAL ENDOPEPTIDASE INHIBITORS | PFIZER LIMITED (GB) | 2004-07-08 | — | — | WO | disclosed |
| EP-1214303-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Merck & Co., Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001016121-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | MERCK & CO., INC. (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082896-A1 | Tetrahydroquinoline derivatives and a process for preparing the same | CETP, MTTP, NPC1L1 | POLB 3983/4885MAPK1 3176/4885ATM 3768/4885 |
| US-20200181138-A1 | TETRAHYDRONAPHTHYRIDINEPENTANAMIDE INTEGRIN ANTAGONISTS | ITGAV, ITGB3, ITGA4 | POLB 4204/4885MAPK1 2531/4885ATM 2952/4885 |
| US-11192889-B2 | Tetrahydronaphthyridinepentanamide integrin antagonists | ITGAV, ITGB3, ITGA4 | POLB 4204/4885MAPK1 2531/4885ATM 2952/4885 |
| US-20040138274-A1 | Cardiovascular disorders; hypotensive agents; endopeptidase inhibitor; sexual disorders | MME, ECE1, ECE2 | POLB 3713/4885MAPK1 2445/4885ATM 4873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.